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EQUIPTT: The Evaluation of the QUiPP app
for Triage and Transfer protocol for a
cluster randomised trial to evaluate the
impact of the QUiPP app on inappropriate
management for threatened preterm
labour
Helena A. Watson* , Naomi Carlisle, Katy Kuhrt, Rachel M. Tribe, Jenny Carter, Paul Seed and Andrew H. Shennan
Abstract
Background: Accurate diagnosis of preterm labour is needed to ensure correct management of those most at risk of
preterm birth and to prevent the maternal and fetal risks incurred by unnecessary interventions given to the large
majority of women, who do not deliver within a week of presentation. Intervention “just-in-case” results in many
avoidable admissions, women being transferred out of their local hospital unnecessarily and most women receiving
unwarranted drugs, such as steroids and tocolytics. It also precludes appropriate transfers for others as neonatal cots
are blocked pre-emptively, resulting in more dangerous ex-utero transfers. We have developed the QUiPP App which is
a clinical decision-making aid based on previous outcomes of women, quantitative fetal fibronectin (qfFN) values and
cervical length. It is hypothesised that using the QUiPP app will reduce inappropriate admissions and transfers.
Methods: A multi-site cluster randomised trial will evaluate whether the QUiPP app reduces inappropriate
management for threatened preterm labour. The 13 participating centres will be randomly allocated to receive either
intervention or control. If the QUiPP app calculates risk of delivery within 7 days to be is less than 5%, clinicians are
advised that interventions may be withheld. Women’s experience of threatened preterm labour assessment will be
explored using self-completed questionnaires, with a subset of participants being invited to semi-structured interview.
A health economics analysis is also planned.
Discussion: We hypothesise that the QUiPP app will improve identification of the most appropriate women for
admission and transfer and ensure that therapies known to reduce risk of preterm neonatal morbidities are offered to
those who need them. We will determine which women do not require these therapies, thereby reducing over-
medicalisation and the associated maternal and fetal risks for these women. The findings will inform future national
guidelines on threatened preterm labour. Beyond obstetrics, evaluating the impact of an app in an emergency setting,
and our emphasis on balancing harms of over-treatment as well as under-treatment, make EQUIPTT a valuable
contribution to translational medicine.
Trial registration: The EQUIPTT trial was prospectively registered on 16th January 2018 with the ISRCTN
registry (no. 17846337).
Keywords: Preterm birth, Prediction, Fetal fibronectin, Cervical length, QUiPP app
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Background
Women with symptoms of preterm labour have long
posed a diagnostic challenge for clinicians concerned with
managing the risks of preterm birth when the reality is
that most women will not deliver imminently [1]. Various
prediction methods are available to direct interventions
that delay or ameliorate the consequences of preterm
birth (e.g. in-utero transfer, tocolysis, antenatal corticoste-
roids). However these interventions have psychological,
economic and clinical implications if given unnecessarily.
In light of recent UK guidance to treat all women in
threatened preterm labour (TPTL) prior to 30 weeks [2],
most of these women are likely to be admitted. However,
the majority of women presenting with symptoms of
preterm labour will not deliver in seven days [1].
Risks associated with antenatal corticosteroids
Clinicians are familiar with steroid-induced glucose in-
tolerance in the mother, necessitating insulin/dextrose
infusions and prolonged admissions. However, fetal ex-
posure to steroids has become the over-arching concern.
There is a significant reduction in infant birthweight of
those women exposed to antenatal corticosteroids who
deliver more than seven days after the first dose, com-
pared to those receiving no treatment (mean difference
147 g, 95% CI -291.97 to − 2.05 g) [3]. Infants exposed to
steroids are at increased risk of neonatal hypoglycaemia
(1.61 CI 1.38–1.87) and are significantly more likely to
be in the lower quartile of academic ability (p = 0.01)
(ARR 9.2–17.7% to 8.5%) [4]. There is biological plausi-
bility supporting the latter finding given evidence of de-
creased brain growth in preterm and term infants
exposed to antenatal corticosteroids in animal studies
[5]. There is also evidence that fetal exposure to gluco-
corticoids modifies fetal hypothalamic-pituitary-adrenal
function, which is associated with increased risk of car-
diovascular and metabolic diseases in adulthood [6, 7].
Structural development of the brain may also be affected
by steroid exposure, such as impaired cortical folding [8]
and cortical thinning [9].
Risks associated with unnecessary in-utero
transfer
Appropriate antenatal in-utero transfer (as opposed to
ex-utero) is essential to avoid the significant increases in
neonatal morbidity and mortality associated with post-
natal transport of preterm infants [10]. In some units a
treat-all policy for threatened preterm labour would dra-
matically increase the number of such transfers. The im-
plications of this far exceed the ambulance transfer
costs: being transferred to another hospital unit (out of
area) is associated with a significant stress and expense
for the parents and family [11]. There is an immediate
clinical burden of transfer arrangements, which involves
a number of on-call obstetric, neonatal and midwifery
teams and takes an average of 340 min to complete [12].
This does not include the return journey time of the
transferring midwife. Paradoxically, unwarranted ante-
natal transfers may increase more dangerous postnatal
transfers by impairing efficient management of neonatal
cots (i.e. cots reserved for babies that do not actually de-
liver preterm). With these neonatal cots blocked, infants
of women in true preterm labour are only able to be
transferred postnatally.
Maternal risks
Hospitalisation also increases the risks of venous
thromboembolism, hospital-acquired infections and the
psychological strain for the mother.
Our research group has developed the QUiPP App,
which improves prediction of preterm labour by com-
bining clinical parameters and calculates risks more pre-
cisely from continuous variables, to better assess risk
[13–15]. It utilises quantitative fetal fibronectin (qfFN)
(a protein released into the vagina at high concentra-
tions during preterm labour), the use of which has been
developed by our group [13–15]. In a prospective obser-
vational study of 300 women, we reported a negative
predictive value (NPV) for qfFN at < 10 ng/mL of 98.2%,
and a positive predictive value (PPV) for delivery < 34
weeks at a 200 ng/mL threshold of 37% [13]. The value
is limited by these arbitrary thresholds, and we showed
that improved prediction can be obtained by interrogat-
ing the data across the whole qfFN range i.e. better sen-
sitivity and “rule out” at low levels and improved
specificity and “rule in” at high levels. We combined
qfFN and cervical length measurements (also as a con-
tinuous variable) to improve the prediction further in
1249 asymptomatic women [14]. We then created a pre-
dictive model from a prospective observational dataset
of 382 women with TPTL to provide an individualised risk
of delivering within 1/2/4 weeks and before 30/34/37
weeks [15]. The accuracy of the model was further con-
firmed using a validation set and performance reliability
demonstrated by comparison of expected and observed
sPTB rates (p > 0.05). Receiver operating characteristic
areas in the validation set differed from the training set by
amounts between − 0.04 and + 0.02 [15]. The model was
subsequently updated on a larger dataset comprising 1032
women presenting with symptoms of TPTL, and this is
the analysis that is incorporated into the latest version of
the QUiPP app.
In terms of guiding management decisions, the major-
ity of cases are assigned a very low-risk (< 1%) by QUiPP
app, which clearly indicates a “no admit” strategy. In
EQUIPTT, we provide a guidance threshold of 5% risk
of delivery within seven days for intervention, based on
our previous published work [16]. However, given the
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other multiple variables that contribute to this decision
(such as gestational age), and our intention for the
QUiPP app to be a tool to help clinicians make their
own decisions, we have refrained from dogmatic recom-
mendation based on absolute thresholds.
We also want to establish if use of the QUIPP app re-
duces women’s anxiety and/or helps her to come to de-
cisions about her care that she is happy with. Women
may have different preconceptions about the significance
of symptoms of TPTL and varying perspectives on con-
sequences of admission and or transfer, such as financial
anxieties and separation from family, friends and other
children [11]. Furthermore, the use of an app to guide
clinical management is new to healthcare practice. Given
the importance of shared decision-making emphasized
by the Montgomery ruling [17], women’s views regard-
ing its application in threatened preterm labour will be
central to the future development of the QUIPP app.
Methods/design
Trial objectives
Our aim is to evaluate the ability of the QUIPP app to re-
duce inappropriate management of TPTL. This will exter-
nally validate the prediction model, assess its success as a
clinical decision making tool, and measure its potential
cost-saving impact in the emergency obstetric setting.
Hypothesis: The implementation of the QUIPP app and
management algorithm will decrease inappropriate
management for TPTL
Trial design
EQUIPTT is a cluster randomised controlled trial (incorp-
orating a parallel group design) across 13 obstetric centres.
This design was chosen as for this scale of protocol inter-
vention (in an emergency situation), it would be challen-
ging to randomise at participant level, affecting uptake
and generalisability of the findings, and individual clini-
cians cannot be randomised to varying decision-making
with individual patients.
The pragmatic approach was taken to introduce the
QUIPP app to entire hospital antenatal units, as stand-
ard practice for all clinicians, and all affected pregnan-
cies. Using this parallel cluster studies have the added
value of limiting the time-bias which occurs with a
stepped wedge design. Also, unlike in a crossover design,
the intervention does not need to be retracted from the
cluster, avoiding contamination bias. Individuals within a
cluster tend to have more similar outcomes than across
clusters. The similarity in the outcomes of individuals
within a cluster within a time period is typically mea-
sured by the within-cluster within-period intra-cluster
correlation coefficient. If this is not factored into the
power calculation and analysis, the effectiveness of the
intervention may be exaggerated [18].
All 13 centres will provide data related to the principal
outcome under their current practice in a six-week
pre-intervention data collection period. Following random-
isation, the centres will use intervention (using the QUiPP
app) or control (routine management) for a nine-month
analysis period. In the final phase of the trial, the interven-
tion will be introduced in the 6 control units. Following
this, data will be collected for a further six weeks across all
13 sites, in order to equally incentivise all sites to partici-
pate. The QUIPP app approach will be adopted as standard
practice in all sites if successful. A list of the study sites is
available from the authors on request.
An health economics analysis will also be conducted; this
will involve a cost-minimisation and cost-consequences
analysis of the use of the QUIPP app for triage and transfer
compared to current practice. We hypothesise that there
will be no negative impact on the health and wellbeing of
women and neonates, as a result of the intervention, par-
ticularly given its non-invasive nature and that the inter-
vention will be cost saving.
Women’s experience of TPTL assessment will be ex-
plored using self-completed questionnaires, with a subset
of participants being invited to semi-structured interview.
Sample size
For inappropriate admission decisions, a total sample size
of 580, approximately 50 recruits per site, was calculated.
Data from our group’s ongoing prospective observational
study into the ability of qfFN to predict preterm birth in
symptomatic women (PETRA REC Ref. 14/LO/1988) has
allowed us to estimate the likely treatment effect for the
intervention reducing inappropriate admissions from 25
to 10% and intra-class correlation 0.030. Based on 13 clus-
ters this treatment effect requires approximately 580 for
80% power. We are aware that a larger number of centres
would also be preferable, but believe 13 is adequate and at
the limit of what is currently feasible.
For our qualitative questionnaires, we have estimated a
target recruitment of 300 participants, 25 recruits per site,
allowing for non-compliance and data collection errors.
Based on previous research involving visual analogue scale
(VAS) scores [19], a total sample size of 272 was required
at standard levels of significance (alpha = 0.05 two-sided) to
achieve 90% power to detect a 10% difference in mean VAS
scores between hospitals with and without the intervention.
Randomisation
Randomisation is at the cluster level. Centres have been
randomly allocated to receive either intervention or con-
trol. Due to there being an odd number of centres, seven
sites were allocated to one group and six to the other.
Minimisation of the randomisation list was not appropriate
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for this design but the imbalances between three levels of
NICU facility at intervention and control sites were small
(4:3, 3:2, and 0:1). TPTL rates were known for 10 sites and
the difference between the average rates at control and in-
terventions sites were within chance (72 and 89%).
Data analysis
Cluster randomised trial
Data analysis will follow the intention to treat principle,
according to the planned intervention. Data will be ana-
lysed using Stata software Version 14 or later (StataCorp,
College Station, Texas) to estimate the size and test for
statistical significance of any effects of the intervention
on primary and secondary, and analysis will be super-
vised by the trial statistician, Mr. Paul Seed. A per proto-
col analysis will also be performed, excluding those who
are incidentally admitted or treated for reasons unrelated
to preterm labour. Treatment effects for binary end-
points will be expressed as risk ratios (relative risk) with
95% CIs, using binomial regression and adjusting for
variables used in the minimization process. Risk differ-
ences will also be calculated for the primary endpoint.
The analysis model will include a random effect for clus-
tering and adjusted standard errors for clustering. Adjust-
ments will also need to be made for differences between
cluster populations, such as ethnicity and maternal age.
Our primary outcome of inappropriate decisions will be
measured per 1000 deliveries.
Health economics evaluation
For the health economics analysis, a multi-level general
linear model using appropriate family and link function,
will be used to calculate the average cost per participant of
use of the QUIPP app for triage and transfer compared to
current practice. Costs will also be reported alongside sec-
ondary clinical outcomes as part of a cost-consequences
analysis. We are not conducting a cost per quality adjusted
life year (QALY) analysis (also called cost-utility analysis)
given the hypothesis that the intervention is cost saving
and does not result in any health decrement. These as-
sumptions make a cost per QALY analysis redundant. Any
health improvement will be captured by adverse incident
reporting and secondary maternal and neonatal clinical
outcomes, which will be reported alongside costs as part
of the cost-consequences analysis.
Women’s experience study (EQUIPTT-Q)
When feasible (i.e. participants identified prior to assess-
ment and staff available to obtain consent), participants in
the cluster randomised trial will be invited to complete a
questionnaire booklet. This includes questions about her
symptoms, anxiety levels before and after her clinical as-
sessment, the tests she received, her options for further
management and the extent to which she is content with
the decisions made. Anxiety levels and decisional conflict
will be ascertained by visual analogue scale (VAS), and the
Decisional Conflict Scale (DCS) questions [19]. The ques-
tionnaire booklet has been designed in collaboration with
the Women’s Health Academic Centre’s Preterm Birth
Studies public and patient involvement (PPI) panel. Differ-
ence in VAS anxiety scores between women before and
after assessment, and between hospitals with and without
QUIPP app in use at the time of assessment, will be calcu-
lated (paired and independent samples t-test). Difference
between DCS scores after assessment, between hospitals
with and without QUIPP app in use, will also be calcu-
lated (paired and independent samples t-tests as appropri-
ate). If the DCS and VAS data is found to be not normally
distributed, non-parametric equivalent tests will be used.
A subgroup of participants (approx. 20–30) will be invited
to provide a more in-depth account of their experiences
during one-to-one face-to-face or telephone interviews. The
interview schedule will be determined following interim
analysis of the data and free text box comments. The
Framework approach [20] will be used to analyse the
qualitative data obtained from the interviews. This
method of qualitative data analysis is suitable for use
with the anticipated findings from this study. Data will
be analysed using NVivo software.
Data collection
Local research staff will prospectively collect data on all
available eligible episodes of threatened preterm labour.
Key data for all patients (at control and interventions sites)
 Hospital number
 Gestation at presentation
 Quantitative fetal fibronectin values (if available)
 Cervical length measurements (if available)
 Current NICU availability
 IUT attempt planned.
 Patient characteristics (age, parity, ethnicity, risk
factors for preterm labour)
 Outcome data as outlined above (5.1 and 5.2).
Anonymised participant data will be transcribed on to
the study database prepared for the trial by MedSciNet
(Stockholm, Sweden).
Anonymous data will be stored on the Preterm Clinical
Network (PCN) Database (REC Ref. 16/ES/0093). Identi-
fiers (initials, date of birth, hospital and NHS number) re-
quired to ensure accurate outcome data collection will be
stored on the separate, but linked, PCN Patient Details
Database which is only accessible to local site users.
Women will be followed up until postnatal discharge.
Neonates will be followed up to discharge or 28 days
(whichever is sooner). Local research staff will monitor
expected dates of delivery and ensure timely collection
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of pregnancy outcomes. Outcome data (medical and
economic) will be collected by review of obstetric hand-
held/electronic notes. Outcome data for women who are
transferred outside their local unit will be obtained by
contacting the referral hospital. The Emergency Bed Ser-
vice and Neonatal Transport Service are supportive of
the study and can assist us in tracking patients who are
not accommodated in their local hospital.
For the health economics analysis data will be col-
lected from routine medical records on antenatal admis-
sions, length of stay, outpatient appointments, day cases
and scans for women identified as participants in the
trial from the time of first being identified as part of the
trial until discharge following delivery. Healthcare re-
source group codes for each event will be collected and
costs from National Reference costs applied. We will
conduct a time and motion study of clinician time and
resources spent identifying a suitable transfer location
on a sample of transfers. We will also conduct a micro
costing of the cost of a transfer. We will also collect and
report statistics and costs per patient for mode of deliv-
ery for women identified as participants in the trial and
ex-utero transfers and NICU stays for their neonates
(adjusting for non-singleton births). We will include the
cost of the intervention which will include the cost of any
training and the cost of clinician time associated with
using the app. This information will be collected from the
app, patient notes and a time and motion questionnaire
administered to clinicians for a subset of patients.
For the women’s experience study (EQUIPTT-Q) partici-
pants, following consent, the researcher will enter the
woman’s initials, hospital number, date of birth and date of
signing consent against the next consecutive EQUIPTT-Q
ID number on the EQUIPTT-Q register. This ID number
will be entered on the consent form and alternative pages
of the questionnaire booklet. The participant will be asked
to complete part 1 (questions regarding baseline demo-
graphics, her symptoms and anxiety levels prior to assess-
ment) straight away. She will be asked to keep the booklet
with her and to complete part 2 (tests, planned interven-
tions, anxiety post assessment and decisional conflict scale
questions) after her clinical assessment. She will then hand
the completed booklet back to staff before leaving the unit.
The researcher checks the booklet for completion and en-
ters data on EQUIPTT-Q datasheet (spreadsheet). The
datasheet (which contains no identifiable data) is emailed
to trial management team on a weekly basis. Data will be
merged into the EQUIPTT-Q SPSS database which is sep-
arate from the main trial database.
Participants selected for interview will be contacted
and given further verbal and written information. If will-
ing, arrangements will be made at a time and place con-
venient to the participant and they will be asked to sign
a consent form prior to the interview taking place. This
may be via telephone or face-to-face. The interview
schedules will be designed following interim analysis of
the questionnaire data and free text comments, and in
consultation with the preterm birth PPI panel. Inter-
views will be recorded on digital audio equipment and
then transcribed and prepared for analysis.
At the end of the study and once outcomes have been
collected by individual site users, the anonymous data will
be extracted for analysis by HW from the PCN Database
onto an Excel spreadsheet. The spreadsheet will be stored
on a secure password protected computer for review by
two researchers to remove duplicates and participants
with missing data that should not be included in the ana-
lysis (HW and NC). Data cleaning will also be performed
using Stata software Version 14 or later (StataCorp, Col-
lege Station, Texas) by our trial statistician (PS) prior to
analysis. The data extraction method will be piloted dur-
ing the data analysis plan in the 9-month study period to
ensure any potential pitfalls are identified.
Data management
For the randomized cluster trial anonymised data only
will be stored on a secure study-specific internet data-
base (MedSciNet). All Investigators and study site staff
must comply with the requirements of the Data Protec-
tion Act 1998 with regard to the collection, storage, pro-
cessing and disclosure of personal information and will
uphold the Act’s core principles.
Local principal investigators will ensure that the
confidentiality of the patients’ data is preserved. As
permitted by all applicable laws and regulations, lim-
ited participant attributes such as, age or date of birth
may be used to verify the participant and accuracy of
the participant’s unique identification number. Indi-
vidual participant data will not be disclosed outside of
study staff and will not appear on any reports pro-
duced by the sponsor. The following people may also
access these records:
 Study monitors and auditors (including the data
monitoring committee), who may work for the
sponsor or its authorised representatives, who check
that the study is being performed correctly and that
the information collected is accurate.
 National and international regulatory authorities
involved in keeping research safe for participants.
Participant information provided by the EQUIPTT-Q
questionnaire will be labelled with a unique EQUIPTT-Q
identification number. It will not include and patient-identi-
fiable information. In order to arrange the interviews, the
contact details (email, phone number) of willing partici-
pants will be obtained from hospital records only if the par-
ticipant has been selected for interview.
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Published results will not contain any personal data
that could allow identification of individual participants.
A data monitoring committee (DMC), independent
from the sponsor, will evaluate outcome data (e.g. ad-
verse neonatal outcomes and maternal hospitalisation)
in a blinded fashion at regular intervals through the trial
with the ability to report any clinical concerns that may
arise from the blinded data. Because of the parallel clus-
ter design, data will only be available on the unmasked
results at the end of the trial. Depending on the DMC’s
requests, the closed DMC session will be able to con-
sider the results of the primary maternal and neonatal
endpoints in both arms of the trial and any Serious Un-
expected Adverse Events and form a view on whether it
is ethical for the trial to continue.
Selection of participants
Main study inclusion criteria
 Pregnant women with symptoms of TPTL
(contractions or abdominal pain)
 Between 23+ 0 and 34+ 6 weeks
 Capacity for quantitative assessment of fetal
fibronectin and/or transvaginal ultrasonic cervical
length if randomised to the intervention group.
Main study exclusion criteria
 Definitive diagnosis of labour (i.e. regular painful
contractions with cervical change > 3 cm on
speculum or digital examination)
 Confirmed ruptured membranes (on speculum
examination)
 Significant vaginal bleeding
Women’s experience (EQUIPTT-Q) study inclusion criteria
 Pregnant women with symptoms of threatened
preterm labour (contractions or abdominal pain)
 Between 23+ 0 and 34+ 6 weeks
Women’s experience (EQUIPTT-Q) exclusion criteria
 Unable or unwilling to give informed consent
 Under 16 years of age
 Unable to understand English language sufficiently
to complete the questionnaire booklet
Implementing the QUiPP app intervention
In each phase, each cluster will recruit consecutive women
with singleton or twin pregnancies presenting between
23+ 0 and 34+ 6 weeks presenting with symptoms of pre-
term labour. Eligible participants will be identified at
labour ward and day assessment triage by the direct care
team and local research support teams. Inclusion and ex-
clusion criteria are defined above.
All sites will receive training on the use of the QUIPP
App and management guidance prior to its introduction,
and periodically throughout the trial at peaks of staff
turnover. This training will be delivered by the trial team
at different times and locations to suit each site, for ex-
ample, at departmental audit meetings and staff induc-
tion. Training will be delivered via clinical vignettes
which provide opportunity for the clinicians to use the
app in a training environment. Aide-memoires such as
lanyards and pens are provided to each site to encourage
use of the app. The doctor/midwife assessing the woman
inputs the gestation, previous history of late miscarriage
or preterm birth, quantitative fetal fibronectin value
and/or ultrasonic cervical length into the app and the
app provides % risk of delivery within 1/2/4 weeks and
before 30/34/37 weeks. The exact thresholds for admis-
sion or treatment are gestation-dependent and may need
to be tailored to individual circumstances. However as a
recommendation, our guidance will suggest a 5% risk of
delivery within 7 days as threshold for antenatal cortico-
steroid administration, admission, and/or in-utero trans-
fer. Ultimately however the management decisions
following the knowledge provided by the QUIPP app will
remain the clinicians’ responsibility. A feedback option is
available on the app to directly contact the trial team with
specific non-clinical queries. Incentives and competitions
will also aim to increase recruitment for the qualitative
recruitment.
Outcomes
Primary outcomes
Our primary outcome of inappropriate management for
threatened preterm labour is defined by:
 number of inappropriate admission decisions:
admitted and delivery interval > 7 days OR not
admitted and delivery interval < 7 days
and
 number of inappropriate in-utero transfer decisions/
actions: in-utero transfers that occurred or were
attempted > 7 days prior to delivery, and ex-utero
transfers within 24 h that should have been in-utero
(attempted and non-attempted)
Secondary outcomes
Secondary outcomes will include:
 All components of primary outcome individually
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 Maternal clinical outcomes (e.g. new onset
gestational diabetes, thromboembolic disease and
confirmed sepsis)
 Neonatal clinical outcomes (e.g. neonatal death prior
to discharge, gestational age at delivery, birthweight,
days of supplemental oxygen)
 Process measures (days of maternal hospitalisation,
steroid, tocolytic and magnesium sulphate
administration, neonatal intensive-care admissions,
ex-utero transfer within 24 h of delivery)
 Compliance to management recommendations
Information will also be collected on the number of
preterm deliveries before 34, and 37 weeks, and on the use
of treatments to prevent prematurity [antibiotics, cerclage
(by site), progesterone]. The authors may be contacted for
samples of the data collection forms.
Health economic outcomes
Cost-savings will be generated as a result of:
 Reduction in the number of inappropriate admission
decisions.
 Reduction in the number of inappropriate in-utero
transfer decisions.
Women’s experience study (EQUIPTT-Q)
Our key outcome is difference in VAS anxiety scores be-
tween women before and after assessment, between hos-
pitals with and without QUIPP app in use at the time of
assessment. We will also analyse difference between
DCS scores after assessment, in hospitals with and with-
out QUIPP app in use.
Discussion
Management of TPTL has represented a clinical conun-
drum for decades. Intervention “just-in-case” results in
many unnecessary admissions, women being transferred
out of their local hospital unnecessarily and most women
receiving unnecessary drugs, such as steroids and tocoly-
tics. It also prevents appropriate transfers as neonatal cots
are blocked unnecessarily, resulting in more dangerous
ex-utero transfers. One reason for the current trend for
over-treatment of TPTL is concern that the false-negatives
any triage system entails. This study will determine the
risks and benefits of limiting management and treatment
to those most at risk of delivery.
The exact thresholds for admission or treatment are
gestation-dependent, may need to be tailored to individ-
ual circumstances and will remain the clinicians’ respon-
sibility. As a recommendation, our guidance will suggest
a 5% risk of delivery within seven days as threshold for
antenatal corticosteroid administration, admission, and/
or in-utero transfer. A 5% threshold is equivalent to an
odds of 5:95 which is 1:19. This estimates the harm of a
missed imminent delivery (a false negative) is 19 times
as great as the harm of overtreatment (a false positive).
It was found to be an acceptable threshold for interven-
tion in our Delphi survey of preterm birth specialists. In
the context of national guidance which advocated more
intervention and disregarded the risk of harm this incurs
to the majority [2], this study’s comprehensive evaluation
of the true clinical impact of the QuiPP app will deter-
mine and justify an appropriate threshold for TPTL
intervention for the first time.
If, as we hypothesise, the QUIPP app improves selec-
tion of the appropriate women for admission and trans-
fer, it will ensure that therapies known to reduce risk of
preterm neonatal morbidities are offered to those who
need them and reduce the associated maternal and fetal
risks to women who do not. Conversely if a treat-all pol-
icy is justified, we can help define resource use and
clinical need to inform policy makers. Beyond obstetrics,
evaluating the impact of an app in an emergency setting,
and our emphasis on balancing harms of over-treatment
as well as under-treatment, make EQUIPTT a valuable
contribution to translational medicine.
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